Has dasatinib been included in medical insurance when it is launched in China?

Dasatinib (Dasatinib) is a targeted drug mainly used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). This drug prevents tumor cell proliferation by inhibiting the activity of BCR-ABL tyrosine kinase. In China, dasatinib has received marketing approval and is reimbursed within the scope of medical insurance, which is undoubtedly positive news for patients.

However, it is worth noting that health insurance reimbursement for dasatinib is not universal, but is limited to patients who meet certain conditions. This means that only those patients who have been confirmed by a doctor and meet the standards specified by the medical insurance can enjoy the reimbursement of the drug. This policy aims to ensure the rational allocation of medical resources and encourage patients to receive standardized treatment under the guidance of professional doctors. Although medical insurance coverage can reduce patients' financial burden, many patients may still face high out-of-pocket expenses, which to a certain extent affects their treatment choices and compliance.

On the market, the common specifications of dasatinib include50mg 60 tablets and 20mg 60 tablets, with each box selling for about 10,000 yuan. Compared with foreign markets, the price of dasatinib is still higher in China, but the coverage of medical insurance allows more patients to obtain this important treatment option. In foreign markets, the price of dasatinib is generally higher, usually reaching more than 10,000 US dollars. Against this background, the accessibility of domestic drugs is relatively better, especially with the support of medical insurance, and many patients are able to achieve better treatment results.

In summary, the launch of dasatinib in China and its inclusion in medical insurance provide new treatment options for patients with chronic myelogenous leukemia and acute lymphoblastic leukemia. Although there are certain restrictions in the reimbursement policy, as patients' awareness of the drug increases and medical policies gradually improve, it is expected that more patients will be able to benefit from this innovative drug.

Reference materials:https://go.drugbank.com/drugs/DB01254